|
Post by centralcoastinvestor on Sept 27, 2016 15:55:38 GMT -5
That would work if the shorts were simply seeking profit. However, I think they are on a mission to totally destroy MNKD, wipe out Afrezza and thus protect their multi billion dollar insulin markets. Otherwise why would there be 100,000,000 shares short in a 61 cent? From their perspective the answer would be the prospect of making $61 million. To be frank, $61 million is chump change on Wallstreet. Particularly given the huge potential downside if some surprise news causes the price to gap up. The massive short position has never made sense and makes much less sense now unless there is another reason as Avogadro suggests.
|
|
|
Post by mannmade on Sept 27, 2016 17:08:18 GMT -5
The other reason is for those who shorted at a higher price and have yet to cover... imho...
|
|
|
Cash
Sept 27, 2016 17:25:09 GMT -5
via mobile
saxcmann likes this
Post by madog365 on Sept 27, 2016 17:25:09 GMT -5
The other reason is for those who shorted at a higher price and have yet to cover... imho... Of coursedthey shorted at higher levels , there is much more then 61m at stake.. I believe it was shkreli who claimed to have shorted a million shares probably somewhere around 5 bucks or so. What would that put him up about now? Ans he's a small fish. There's 100m short.
|
|
|
Post by lakers on Oct 1, 2016 1:19:52 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Cash
Oct 1, 2016 2:04:24 GMT -5
cm5 likes this
Post by Deleted on Oct 1, 2016 2:04:24 GMT -5
Agree, but you're forgetting how enormous the market is for inhaled VLP vaccines, aka TechnoVax.
|
|
|
Cash
Oct 2, 2016 12:03:00 GMT -5
Post by audiomr on Oct 2, 2016 12:03:00 GMT -5
Nothing has happened with TechnoVax in years. The last news item on its website is from March 2013.
|
|
|
Post by lakers on Oct 2, 2016 14:17:50 GMT -5
Examples of drugs acquired at IND stage. It's time to deal the EpiHale or PAHale card from the bottom up to avoid further SH dilution and delisting. It's ironic that Mnkd spent $2.9B on Afrezza but those 2 cards might be the ones that rescue the company. NanoAntibiotics Acquires Company Developing Novel Therapies for Liver Disease Announces New Company Name -- BioVie, Inc. BEVERLY, MA--(Marketwired - Apr 18, 2016) - NanoAntibiotics Inc. (OTCQB: NNAB) (the "Company"), a development stage company focused on the discovery, development, and commercialization of novel drug therapies, is pleased to announce the acquisition of LAT Pharma LLC, of Chicago, IL, an early-stage biotechnology company developing novel medicines to treat life-threatening complications of liver cirrhosis. LAT Pharma brings a promising new therapeutic opportunity to NanoAntibiotics. Earlier this year LAT Pharma met with the FDA to discuss a submission for a novel therapy to treat ascites due to liver cirrhosis. The meeting designated as a "pre-investigational new drug (IND) meeting," provided guidance that is currently being addressed. The Company's goal is to commence a clinical trial program in human subjects upon FDA clearance of the IND application. m.marketwired.com/press-release/nanoantibiotics-acquires-company-developing-novel-therapies-for-liver-disease-otcqb-nnab-2115659.htmROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR LLC to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile (C. diff) infection, the leading cause of hospital acquired infections (HAI), that may occur secondary to treatment with antibiotics. The assets include a pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents intended to support an IND and Biologic License Application (BLA) with the FDA www.syntheticbiologics.com/news-media/press-releases/detail/82/synthetic-biologics-to-acquire-clinical-stage-c-difficile
|
|
Deleted
Deleted Member
Posts: 0
|
Cash
Oct 2, 2016 15:32:36 GMT -5
cm5 likes this
Post by Deleted on Oct 2, 2016 15:32:36 GMT -5
Nothing has happened with TechnoVax in years. The last news item on its website is from March 2013. Wrong. Apparently you have not been keeping up with them. They updated their website this year. They have published several patents this year and, actually, here is their latest published research from June 2016: • Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein technovax.com/wp-content/uploads/2013/06/Clin.-Vaccine-Immunol.-2016-Cimica-451-9.pdfTechnoVax is alive and well.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 14, 2016 8:09:38 GMT -5
Same question as my original post to start this thread. Where are we going to get cash from?
How is MNKD going to get enough cash in a way that won't decimate existing shareholders? 1- Dilution better than BK but if they raise via equity, it will be crushing if even possible with a SP of 0.54. 2- RLS money coming in? Don't bet on it. 3- Sanofi coming up with $$, maybe but its not like MNKD has leverage with them. 4- No assets to lend against, all spoken for. 5- Epi deal or other deal, what when and how much?
Be nice to break even when the dust settles on this thing but not sure I see a way to raise $$ at this point?
Thoughts? I'm all ears.
|
|
|
Cash
Oct 14, 2016 9:38:37 GMT -5
Post by matt on Oct 14, 2016 9:38:37 GMT -5
Scotta, that is a realistic view of the world and I think your option 1 is the only one likely to happen, if at all. While scripts are doing better they need to be on an exponential trajectory and they are not. Dilution is the only way to lengthen the runway sufficiently to have a chance at survival without a trip through BK court, but that raise will have to come from some "hard money" sources and they will be increasingly reluctant to play as the weeks go by.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 14, 2016 10:33:33 GMT -5
MNKD is or should be in survival mode, imo. Realistic options imo includes:
1. taking mnkd private or 2. selling off the company for any price to try and secure the survival of afrezza or 3. more debt 4. more shares 5. restructure the company. Dump the sales force, it's not working. Reduce expenses down to nothing for survival. 6. combination of parts of the above.
Doing a reverse split won't help mnkd without afrezza revenues imo. With little revs, a reverse split will adjust the stock price but it'll simply deflate back down to this level in a short period of time and not likely to entice enough money to invest in mnkd to keep the lights on in its current form, imo.
The best option for mnkd at this point is afrezza sales, imo. They believed, or projected a belief, that they could get sales going. So far, here we are in oct and sales are still non existent. These weekly changes of 10, 20, 30 script counts aren't going to move the needle imo and every week we see a change, it can be up or down a bit with no direction. The market in all of it's layers is speaking volumes and the stock price follows. When it comes to sales, the label is killer. MNKD indicated they are going for a label change but until we see otherwise, I'm in the camp that the label change won't address the major issues and will likely nibble around the edges of the label problems.
So, what can mnkd do to get sales? Last year we heard reasons why afrezza wasnt' selling. Lung testing equipment, insurance coverage, endo's not interested were some of the heavy hitter reasons. Lung testing isn't hard these days with technology and I would like to think that's not the issue. Insurance? Well, I'd add in competition over formulary placement. What can mnkd do to improve it's formulary position? Lower their price to match the label until the label improves. As it is right now, the label doesn't say afrezza is better than the other options and so the insurance industry isn't interested in equal pricing with other products. MNKD needs to reduce afrezza pricing much lower to entice initial interest with the powers that be in this industry. IF they fix that and make getting afrezza less of a hassle through insurance, then mnkd can get to work on the endo's. The days of believing afrezza will sell itself and mass numbers of people will buy it no matter the cost are over, at least through my lens. So, I'd say dump the sales force. They can't sell afrezza to endo's who don't want to deal with the insurance hassle. Until that's resolved (insurance block), no need to call endo's who, it would appear, aren't really listening in mass anyways.
So, restructuring. Dump the sales force and any asset they can still dump and reduce their cash burn down as low as it can possibly get without turning the lights out. Work on the insurance coverage and the label and stop trying to reach endo's using the standard approach, which isn't working. Work on publishing articles for peer review. And continue working with those endo's excited to be using afrezza. No need for a sales force at this point in time. Just wasting much needed money.
|
|
|
Cash
Oct 14, 2016 10:41:04 GMT -5
Post by fiddler on Oct 14, 2016 10:41:04 GMT -5
MNKD is or should be in survival mode, imo. Realistic options imo includes: 1. taking mnkd private or 2. selling off the company for any price to try and secure the survival of afrezza or 3. more debt 4. more shares 5. restructure the company. Dump the sales force, it's not working. Reduce expenses down to nothing for survival. 6. combination of parts of the above. Doing a reverse split won't help mnkd without afrezza revenues imo. With little revs, a reverse split will adjust the stock price but it'll simply deflate back down to this level in a short period of time and not likely to entice enough money to invest in mnkd to keep the lights on in its current form, imo. The best option for mnkd at this point is afrezza sales, imo. They believed, or projected a belief, that they could get sales going. So far, here we are in oct and sales are still non existent. These weekly changes of 10, 20, 30 script counts aren't going to move the needle imo and every week we see a change, it can be up or down a bit with no direction. The market in all of it's layers is speaking volumes and the stock price follows. When it comes to sales, the label is killer. MNKD indicated they are going for a label change but until we see otherwise, I'm in the camp that the label change won't address the major issues and will likely nibble around the edges of the label problems. So, what can mnkd do to get sales? Last year we heard reasons why afrezza wasnt' selling. Lung testing equipment, insurance coverage, endo's not interested were some of the heavy hitter reasons. Lung testing isn't hard these days with technology and I would like to think that's not the issue. Insurance? Well, I'd add in competition over formulary placement. What can mnkd do to improve it's formulary position? Lower their price to match the label until the label improves. As it is right now, the label doesn't say afrezza is better than the other options and so the insurance industry isn't interested in equal pricing with other products. MNKD needs to reduce afrezza pricing much lower to entice initial interest with the powers that be in this industry. IF they fix that and make getting afrezza less of a hassle through insurance, then mnkd can get to work on the endo's. The days of believing afrezza will sell itself and mass numbers of people will buy it no matter the cost are over, at least through my lens. So, I'd say dump the sales force. They can't sell afrezza to endo's who don't want to deal with the insurance hassle. Until that's resolved (insurance block), no need to call endo's who, it would appear, aren't really listening in mass anyways. So, restructuring. Dump the sales force and any asset they can still dump and reduce their cash burn down as low as it can possibly get without turning the lights out. Work on the insurance coverage and the label and stop trying to reach endo's using the standard approach, which isn't working. Work on publishing articles for peer review. And continue working with those endo's excited to be using afrezza. No need for a sales force at this point in time. Just wasting much needed money. I agree, but I think it's probably too late to work on the label. Focus instead on insurance coverage. Try to do some deal with a major insurer like Medtronic did with UHC to cover its bound to be more expensive artificial pancreas.
|
|
|
Cash
Oct 14, 2016 10:46:20 GMT -5
Post by u1682002 on Oct 14, 2016 10:46:20 GMT -5
Another option that I hope is that MNKD can indeed sell ~50mil to 100mil Afrezza (with 50% price discount) to "the third country".
|
|
Deleted
Deleted Member
Posts: 0
|
Cash
Oct 14, 2016 11:01:45 GMT -5
Post by Deleted on Oct 14, 2016 11:01:45 GMT -5
Creative idea selling product to another country but I think at this point, another country might have issues about MNKD being a going concern. If sales pick up a bit and cash burn drops, maybe monthly burn goes down to $7mm and then to your point, $55 could allow the company to keep the lights on an additional 7 mos and maybe thats enough runway to get SP up or demonstrate viability to sign up a partner ex-US. The next Q release will let us know if the company continues or dies.
|
|
|
Post by saxcmann on Oct 14, 2016 11:08:25 GMT -5
I think the label has already been submitted for change. I think mnkd cares is handling all insurance issues now. I think mann foundation is another option to help financially. I think scripts need to continue to increase so we can get another partner. I think No to dilution. I think no to R/S. I think time is running out!!
|
|